title: Requirement for CD4+ T cells in the gammadelta T cell proliferative response to Daudi Burkitt's lymphoma.
abstract: Daudi Burkitt's lymphoma cells stimulate the proliferation of Vgamma2 Vdelta2 T cells in human peripheral blood mononuclear cells (PBMC). Transfection studies have established that the gammadelta T cell receptor is sufficient for recognition of a ligand associated with Daudi cells. Since other studies have demonstrated the need for cooperation between alphabeta T cells and Vgamma2 Vdelta2 T cells in the proliferative response to mycobacterial antigens, we used human, unfractionated PBMC and PBMC depleted of specific T cell subsets to determine whether the gammadelta T cell response to Daudi cells also requires cooperation between alphabeta and gammadelta T cells. In the current study, we demonstrate that depletion of CD4+ T cells substantially reduces the overall proliferative response of PBMC to Daudi cells and subsequent gammadelta T cell expansion. IL-2 production by PBMC in response to Daudi cells was also decreased by depletion of CD4+ T cells, but not by depletion of CD8+ or gammadelta T cells. In the CD4+ T-cell-depleted PBMC, proliferation in response to Daudi cells was restored by the addition of IL-2. These data stress the importance of cooperation between alphabeta and gammadelta T cells in the response to some complex antigens.
authors.affiliation: Department of Neurology, Veterans Affairs Medical Center, Salt Lake City, Utah 84148, USA.
authors.forename: J
authors.initials: J
authors.lastname: Burns
authors.forename: S
authors.initials: S
authors.lastname: Lobo
authors.forename: B
authors.initials: B
authors.lastname: Bartholomew
mesh_terms: D001402:B-Lymphocytes / Q000276:immunology; D002051:Burkitt Lymphoma / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D002461:Cell Line, Transformed; D002478:Cells, Cultured; D006801:Humans; D007376:Interleukin-2 / Q000096:biosynthesis / Q000494:pharmacology; D015847:Interleukin-4 / Q000494:pharmacology; D015850:Interleukin-6 / Q000494:pharmacology; D017493:Leukocyte Common Antigens / Q000032:analysis; D008213:Lymphocyte Activation; D008211:Lymphocyte Cooperation; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000276:immunology*; D011994:Recombinant Proteins / Q000494:pharmacology; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
chemical_list: D007376:Interleukin-2; D015850:Interleukin-6; D016692:Receptors, Antigen, T-Cell, gamma-delta; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D015847:Interleukin-4; D017493:Leukocyte Common Antigens